Ceftrimax

Ceftriaxone

Resp tract, ENT, bone, joint & soft tissue, intra-abdominal & genital (including gonorrhea) infections, UTI, sepsis, meningitis & infections in immunocompromized patients. Peri-op prophylaxis.

Adult & childn >12 yr 1-2 g once daily. Severe infections due to sensitive organisms May be increased to 4 g once daily. Childn ≥50 kg Adult dose. Infant 15 days to childn 12 yr 20-80 mg/kg once daily. Infant ≤14 days 20-50 mg/kg once daily. Max: 50 mg/kg. IV dose ≥50 mg/kg should be given via infusion for at least 30 min.

Hypersensitivity.

Check blood profile regularly in long-term use. Patients w/ a history of anaphylactic shock. May cause pseudomembranous colitis in patients w/ diarrhea after receiving antibiotic therapy. Severe liver & kidney dysfunction. Pregnancy & lactation. Neonates especially premature babies. Neonates w/ hyperbilirubinemia.

Diarrhea, nausea, vomiting, stomatitis, glossitis, rash, pruritus, urticaria, allergic dermatitis, edema, exanthema, erythematous multiforme, eosinophilia, bleeding, thrombocytopenia, leucopenia, granulocytopenia, hemolytic anemia, headache, dizziness, anaphylaxis reactions, pain (IM) or phlebitis (IV) at inj site; increased SGOT/SGPT, alkaline phosphatase, bilirubin; increased BUN; moniliasis, vaginitis; diaphoresis & sweating; leucocytosis, lymphocytosis, monocytosis, basophilia, reduced prothrombin time, jaundice, gallbladder sludge, glycosuria, hematuria, anaphylaxis, bronchospasm, serum sickness, abdominal pain, colitis, bloating, dyspepsia, palpitation, epistaxis, biliary lithiasis, agranulocytosis, renal precipitation, nephrolithiasis.

Aminoglycosides, probenecid.

Cephalosporins

J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.

G